Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2019

View Archived Issues

Repair enables regeneration for blood vessels

Prelude Therapeutics initiates phase I study of PRT-543 in advanced malignancies

Phase I results of pegargiminase, cisplatin and pemetrexed in ASS1-deficient high-grade glioma

Discovery and characterization of a novel selective LMP7 inhibitor for multiple myeloma

Novel bispecific T-cell engager CAR therapy overcomes glioblastoma heterogeneity

GlaxoSmithKline presents preclinical data for GSK-102

Development of new long-term animal model of Graves' disease verified

Enrollment open in phase IIb study of dalcinonacog alfa for hemophilia B

Theralase's phase Ib study of TLD-1433 shows 66% CR at therapeutic dose 360 days post treatment

ViGenCell opens enrollment in phase II trial of VT-EBV-N for EBV-positive patients with ENKL

BioArctic receives grant for collaborative research to improve immunotherapy for CNS disorders

Pfizer begins phase I study of PF-06939999 in advanced or metastatic solid tumors

European Commission approves Vizimpro for first-line treatment of EGFR-mutated NSCLC

Daiichi Sankyo presents oral TIP48/TIP49 inhibitors for the treatment of hematological cancer

TUL-001 potently inhibits tumor growth in NSCLC brain metastasis model

Sangamo provides clinical development update

Stem cell-derived human 'hearts' identify new cardiac drugs

Shenzhen Biocan Technologies patents APP-targeting shRNAs

Shenzhen Biocan Technologies identifies new IDO-targeting shRNAs

TNFRSF18-targeting shRNAs described in Shenzhen Biocan Technologies patent

U.S. researchers synthesize antisense oligonucleotides targeting MYC

Bluevalley Pharmaceutical discloses ATR inhibitors

Preclinical results of EI-1071, a selective CSF1R inhibitor regulating tumor-associated macrophages

Comparison of the novel biguanide NT-1195 with metformin/phenformin in endometrial cancer models

Phase I results of highly selective dual IDO1/TDO2 inhibitor M-4112 in advanced solid malignancies